Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1960990 | 0.87 | TLR7 (0.42) | TLR7TLR8 | |
| SCHEMBL1959277 | 0.79 | TLR7 (0.47) | TLR7CNR2TLR8 | |
| SCHEMBL1486644 | 0.75 | TLR7 (0.54) | MRGPRX4TLR7PLA2G2ATLR8 | |
| SCHEMBL12315583 | 0.69 | TLR7 (0.56) | TLR7TLR8 | |
| SCHEMBL1486567 | 0.68 | TLR7 (0.62) | TLR7TLR8 | |
| SCHEMBL1486466 | 0.67 | TLR7 (0.66) | TLR7TLR8 | |
| SCHEMBL1486476 | 0.67 | TLR7 (0.60) | TLR7TLR8 | |
| SCHEMBL1486469 | 0.66 | TLR7 (0.65) | TLR7TLR8 | |
| SCHEMBL1486458 | 0.66 | TLR7 (0.61) | TLR7TLR8 | |
| SCHEMBL1486528 | 0.66 | TLR7 (0.69) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658076-B1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8263594-B2 | Aryloxy and arylalkyleneoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110144099-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144099-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | MRGPRX4 189/4885CYP26A1 593/4885CYP3A4 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.